Centuple Global (531099) 주식 개요체크포인트 트렌드는 인도에서 무역 사업을 하고 있습니다. 자세히 보기531099 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적3/6재무 건전성4/6배당0/6강점주가수익률(12.4x)이 Indian 시장(23.2x)보다 낮습니다.지난 1년간 수익이 5833.9% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(₹187M)높은 수준의 비현금 수입이익 마진 (0.3%)이 지난해 (5.1%)보다 낮습니다.지난 3개월 동안 주가 변동성이 Indian 시장과 비교해 높았습니다.모든 위험 점검 보기531099 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW482,854 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA482,854 investors already sharing narrativesYour Fair Value₹Current Price₹34.2695.0% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m184b2016201920222025202620282031Revenue ₹184.5bEarnings ₹484.6mAdvancedSet Fair ValueView all narrativesCentuple Global Limited 경쟁사Mono PharmacareSymbol: NSEI:MONOPHARMAMarket cap: ₹167.9mRoyal SenseSymbol: BSE:544143Market cap: ₹585.8mNexus Surgical and MedicareSymbol: BSE:538874Market cap: ₹101.2mNovelix PharmaceuticalsSymbol: BSE:536565Market cap: ₹1.4b가격 이력 및 성과Centuple Global 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹34.2652주 최고가₹144.4052주 최저가₹28.22베타0.331개월 변동-12.98%3개월 변동-16.40%1년 변동-18.43%3년 변동n/a5년 변동743.84%IPO 이후 변동1,049.66%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Jul 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹33.46, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 42x in the Healthcare industry in India. Total loss to shareholders of 5.0% over the past year.Board Change • Jul 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. MD, CFO & Director Shubham Chaudhary is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공고 • Jun 20Centuple Global Limited Announces Board AppointmentsCentuple Global Limited at its Extra Ordinary General Meeting held on June 18, 2026, appointed Mr. Gaurav Kaushik as a Non-Executive Independent Director of the company. The company appointed Mr. Ashish Jain as a Non-Executive Independent Director of the company.Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.76 (vs ₹0.046 in FY 2025)Full year 2026 results: EPS: ₹2.76 (up from ₹0.046 in FY 2025). Revenue: ₹5.74b (up ₹5.73b from FY 2025). Net income: ₹15.1m (up ₹14.8m from FY 2025). Profit margin: 0.3% (down from 5.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 112% per year whereas the company’s share price has increased by 111% per year.공고 • May 23Checkpoint Trends Limited to Report Q4, 2026 Results on May 30, 2026Checkpoint Trends Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹44.44, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 756% over the past three years.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹33.46, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 42x in the Healthcare industry in India. Total loss to shareholders of 5.0% over the past year.Board Change • Jul 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. MD, CFO & Director Shubham Chaudhary is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공고 • Jun 20Centuple Global Limited Announces Board AppointmentsCentuple Global Limited at its Extra Ordinary General Meeting held on June 18, 2026, appointed Mr. Gaurav Kaushik as a Non-Executive Independent Director of the company. The company appointed Mr. Ashish Jain as a Non-Executive Independent Director of the company.Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.76 (vs ₹0.046 in FY 2025)Full year 2026 results: EPS: ₹2.76 (up from ₹0.046 in FY 2025). Revenue: ₹5.74b (up ₹5.73b from FY 2025). Net income: ₹15.1m (up ₹14.8m from FY 2025). Profit margin: 0.3% (down from 5.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 112% per year whereas the company’s share price has increased by 111% per year.공고 • May 23Checkpoint Trends Limited to Report Q4, 2026 Results on May 30, 2026Checkpoint Trends Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹44.44, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 756% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹39.28, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 33x in the Healthcare industry in India. Total returns to shareholders of 130% over the past year.Valuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹52.16, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 36x in the Healthcare industry in India. Total returns to shareholders of 1,005% over the past three years.공고 • Mar 18Checkpoint Trends Limited Board Resignations, Effective March 18, 2026Checkpoint Trends Limited announced that based on the recommendations of Nomination and Remuneration Committee meeting held on March 18, 2026 and the Board of Directors of the Company at its meeting held on March 18, 2026 inter alia, considered and approved the following: Resignation of Ms. Bhawna Saunkhiya (DIN: 10683032) as Non- Executive and Independent Director of the Company due to pre-occupation and other personal commitments. Date of Resignation: March 18, 2026. Resignation of Mr. Saurabh (DIN: 10790325) as Non- Executive and Independent Director of the Company. due to pre-occupation and other personal commitments. Date of Resignation: March 18, 2026.New Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹246.5m market cap, or US$2.67m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹85.00, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 38x in the Healthcare industry in India. Total returns to shareholders of 1,701% over the past three years.Reported Earnings • Jan 29Third quarter 2026 earnings releasedThird quarter 2026 results: EPS: ₹1.05. Revenue: ₹1.74b (up ₹1.74b from 3Q 2025). Net income: ₹5.75m (up ₹5.93m from 3Q 2025). Profit margin: 0.3% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has increased by 200% per year, which means it is tracking significantly ahead of earnings growth.공고 • Jan 19Checkpoint Trends Limited to Report Q3, 2026 Results on Jan 28, 2026Checkpoint Trends Limited announced that they will report Q3, 2026 results on Jan 28, 2026Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹120, the stock trades at a trailing P/E ratio of 45.1x. Average trailing P/E is 41x in the Healthcare industry in India. Total returns to shareholders of 2,566% over the past three years.Buy Or Sell Opportunity • Dec 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 118% to ₹109. The fair value is estimated to be ₹90.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 151% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Dec 05Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 189% to ₹110. The fair value is estimated to be ₹90.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 151% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹2.42 (vs ₹0.08 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.42 (up from ₹0.08 loss in 2Q 2025). Revenue: ₹1.09b (up ₹1.09b from 2Q 2025). Net income: ₹13.2m (up ₹13.7m from 2Q 2025). Profit margin: 1.2% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has increased by 170% per year, which means it is tracking significantly ahead of earnings growth.공고 • Nov 04Checkpoint Trends Limited to Report First Half, 2026 Results on Nov 12, 2025Checkpoint Trends Limited announced that they will report first half, 2026 results on Nov 12, 2025공고 • Sep 11Checkpoint Trends Limited announced that it expects to receive funding from Rajvansh Electricals Private Limited, Golden Bio Energy Limited and other investors.Checkpoint Trends Limited announced a private placement to issue 51,436,781 Convertible warrants on September 10, 2025. The transaction involves participation of Rajvansh Electricals Private Limited for 9,074,410 warrant, Golden Bio Energy Limited for 9,074,410 warrant, Recoll Projects Private Limited for 9,074,410 warrant , Pradeep Kumar for 15,124,017 warrant and other investors. Each Warrant will be convertible into, or exchangeable for 1 (one) fully paid-up equity share within 18 (eighteen) months from the date of allotment of the Warrants. The transaction is approved by board of director and still subject to shareholder approval.공고 • Aug 29Checkpoint Trends Limited, Annual General Meeting, Sep 29, 2025Checkpoint Trends Limited, Annual General Meeting, Sep 29, 2025, at 16:00 Indian Standard Time.Reported Earnings • Aug 07First quarter 2026 earnings released: EPS: ₹0.16 (vs ₹0.05 in 1Q 2025)First quarter 2026 results: EPS: ₹0.16 (up from ₹0.05 in 1Q 2025). Revenue: ₹117.1m (up ₹116.1m from 1Q 2025). Net income: ₹889.0k (up 259% from 1Q 2025). Profit margin: 0.8% (down from 25% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 124% per year, which means it is tracking significantly ahead of earnings growth.공고 • Jul 29Checkpoint Trends Limited to Report Q2, 2025 Results on Aug 06, 2025Checkpoint Trends Limited announced that they will report Q2, 2025 results on Aug 06, 2025Reported Earnings • May 30Full year 2025 earnings released: EPS: ₹0.05 (vs ₹0.055 in FY 2024)Full year 2025 results: EPS: ₹0.05 (down from ₹0.055 in FY 2024). Revenue: ₹5.01m (down 56% from FY 2024). Net income: ₹254.0k (down 16% from FY 2024). Profit margin: 5.1% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 14Checkpoint Trends Limited to Report Q4, 2025 Results on May 28, 2025Checkpoint Trends Limited announced that they will report Q4, 2025 results on May 28, 2025New Risk • Mar 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$91k). Market cap is less than US$10m (₹90.0m market cap, or US$1.03m).New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$90k). Market cap is less than US$10m (₹63.3m market cap, or US$723.2k). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).공고 • Feb 03Checkpoint Trends Limited to Report Q3, 2025 Results on Feb 12, 2025Checkpoint Trends Limited announced that they will report Q3, 2025 results on Feb 12, 2025New Risk • Nov 12New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$94k). Market cap is less than US$10m (₹73.8m market cap, or US$874.6k). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).공고 • Nov 05Checkpoint Trends Limited to Report Q2, 2025 Results on Nov 11, 2024Checkpoint Trends Limited announced that they will report Q2, 2025 results on Nov 11, 2024Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹9.75, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 48x in the Healthcare industry in India. Total returns to shareholders of 153% over the past three years.공고 • Sep 16Checkpoint Trends Limited Approves Appointment of Artee Sahu as Company Secretary and Compliance OfficerCheckpoint Trends Limited announced that, the board of directors of the company at its meeting held on September 16, 2024 inter alia, has considered and approved the appointment of Ms. Artee Sahu as company secretary and compliance officer of the company. Date of Appointment is September 16, 2024. Ms. Artee Sahu is a qualified company secretary. She is expert in companies Act 2013 and SEBI (LODR) 2015.공고 • Sep 06Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time.New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹10m revenue, or US$123k). Market cap is less than US$10m (₹43.9m market cap, or US$522.2k). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).Valuation Update With 7 Day Price Move • Sep 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹7.64, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 49x in the Healthcare industry in India. Total returns to shareholders of 40% over the past year.Reported Earnings • Aug 15First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹0.05. Revenue: ₹1.00m (down 50% from 1Q 2024). Net income: ₹248.0k (up ₹788.0k from 1Q 2024). Profit margin: 25% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.공고 • Aug 06Checkpoint Trends Limited to Report Q1, 2025 Results on Aug 13, 2024Checkpoint Trends Limited announced that they will report Q1, 2025 results on Aug 13, 2024Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹8.03, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 107% over the past three years.공고 • May 26Checkpoint Trends Limited Announces Cessation of Sunil Khandalwal as Managing Director, with Effect from May 27, 2024Checkpoint Trends Limited announced that at the board meeting held on May 25, 2024, the company approved the cessation of Mr. Sunil Khandalwal as Managing Director of the Company due to the expiry of tenure and not being reappointed. Date of Cessation- With effect from May 27, 2024.공고 • May 17Checkpoint Trends Limited to Report Q4, 2024 Results on May 25, 2024Checkpoint Trends Limited announced that they will report Q4, 2024 results at 3:30 PM, Indian Standard Time on May 25, 2024Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non Executive Independent Director Harish Surve was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹9.22, the stock trades at a trailing P/E ratio of 32x. Average trailing P/E is 38x in the Healthcare industry in India. Total returns to shareholders of 281% over the past three years.Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.004 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.10 (up from ₹0.004 in 3Q 2023). Revenue: ₹1.71m (down 19% from 3Q 2023). Net income: ₹570.0k (up ₹548.0k from 3Q 2023). Profit margin: 33% (up from 1.0% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹9.27, the stock trades at a trailing P/E ratio of 49.4x. Average trailing P/E is 47x in the Healthcare industry in India. Total returns to shareholders of 331% over the past three years.공고 • Jan 29Checkpoint Trends Limited to Report Q3, 2024 Results on Feb 07, 2024Checkpoint Trends Limited announced that they will report Q3, 2024 results on Feb 07, 2024공고 • Jan 25Checkpoint Trends Limited Announces Resignation of Komal Behl, Company SecretaryCheckpoint Trends Limited announced that Ms. Komal Behl, Company Secretary of the Company has tendered her resignation with effect from January 24, 2024 (at the end of working hours) due to personal reason.Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹4.87, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 41x in the Healthcare industry in India. Total returns to shareholders of 106% over the past three years.Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹0.47 (vs ₹0.02 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.47 (up from ₹0.02 in 2Q 2023). Revenue: ₹2.90m (down 19% from 2Q 2023). Net income: ₹2.59m (up ₹2.49m from 2Q 2023). Profit margin: 89% (up from 2.6% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.공고 • Oct 28Checkpoint Trends Limited to Report First Half, 2024 Results on Nov 07, 2023Checkpoint Trends Limited announced that they will report first half, 2024 results on Nov 07, 2023공고 • Aug 31Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time.Reported Earnings • Aug 17First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₹2.00m (down 61% from 1Q 2023). Net loss: ₹540.0k (down 478% from profit in 1Q 2023).공고 • Aug 03Checkpoint Trends Limited to Report Q1, 2024 Results on Aug 11, 2023Checkpoint Trends Limited announced that they will report Q1, 2024 results on Aug 11, 2023Reported Earnings • May 28Full year 2023 earnings releasedFull year 2023 results: Revenue: ₹11.6m (down 42% from FY 2022). Net loss: ₹785.0k (loss widened 115% from FY 2022).공고 • May 19Checkpoint Trends Limited to Report Q4, 2023 Results on May 26, 2023Checkpoint Trends Limited announced that they will report Q4, 2023 results on May 26, 2023Reported Earnings • Feb 15Third quarter 2023 earnings releasedThird quarter 2023 results: EPS: ₹0.004. Revenue: ₹2.11m (down 51% from 3Q 2022). Net income: ₹22.0k (up ₹430.0k from 3Q 2022). Profit margin: 1.0% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.공고 • Jan 31Checkpoint Trends Limited to Report Q3, 2023 Results on Feb 13, 2023Checkpoint Trends Limited announced that they will report Q3, 2023 results on Feb 13, 2023공고 • Dec 08Checkpoint Trends Limited Announces Company Secretary ChangesCheckpoint Trends Limited announced that Ms. Ritu Chattani, Company Secretary of the Company has tendered her resignation with immediate effect for better prospectus. Ms. Komal Behl, has been appointed as the CompanySecretary and Compliance Officer of the Company with immediate effect. Ms. Komal Behl is a qualified Company Secretary. She is having an experience of over five years in the secretarial field. She has worked as a professional prior to joining Company. Ms. Komal Behl is not related to any of the directors of the company.Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.03 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.02 (down from ₹0.03 in 2Q 2022). Revenue: ₹3.60m (up 39% from 2Q 2022). Net income: ₹93.0k (down 34% from 2Q 2022). Profit margin: 2.6% (down from 5.4% in 2Q 2022). The decrease in margin was driven by higher expenses.공고 • Oct 30Checkpoint Trends Limited to Report First Half, 2023 Results on Nov 10, 2022Checkpoint Trends Limited announced that they will report first half, 2023 results on Nov 10, 2022공고 • Aug 12Rubra Medicaments Limited, Annual General Meeting, Sep 30, 2022Rubra Medicaments Limited, Annual General Meeting, Sep 30, 2022, at 11:00 Indian Standard Time.공고 • Aug 03Rubra Medicaments Limited to Report Q1, 2023 Results on Aug 11, 2022Rubra Medicaments Limited announced that they will report Q1, 2023 results on Aug 11, 2022공고 • May 14Rubra Medicaments Limited to Report Fiscal Year 2022 Results on May 25, 2022Rubra Medicaments Limited announced that they will report fiscal year 2022 results on May 25, 2022공고 • Feb 02Rubra Medicaments Limited to Report Q3, 2022 Results on Feb 11, 2022Rubra Medicaments Limited announced that they will report Q3, 2022 results on Feb 11, 2022Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹3.00, the stock trades at a trailing P/E ratio of 61.4x. Average trailing P/E is 29x in the Healthcare industry in India. Total returns to shareholders of 43% over the past three years.Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹2.71, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 36x in the Healthcare industry in India. Total returns to shareholders of 27% over the past three years.Is New 90 Day High Low • Feb 17New 90-day low: ₹1.87The company is down 12% from its price of ₹2.13 on 19 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 23% over the same period.Reported Earnings • Feb 14Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.00m (down 20% from 3Q 2020). Net income: ₹11.0k (down 94% from 3Q 2020). Profit margin: 1.1% (down from 15% in 3Q 2020).공고 • Feb 01Rubra Medicaments Limited to Report Q3, 2021 Results on Feb 12, 2021Rubra Medicaments Limited announced that they will report Q3, 2021 results on Feb 12, 2021Is New 90 Day High Low • Dec 02New 90-day high: ₹2.22The company is up 14% from its price of ₹1.95 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 30% over the same period.Valuation Update With 7 Day Price Move • Nov 04Market bids up stock over the past weekAfter last week's 20% share price gain to ₹2.16, the stock is trading at a trailing P/E ratio of 37.4x, up from the previous P/E ratio of 31.2x. This compares to an average P/E of 35x in the Healthcare industry in India. Total return to shareholders over the past three years is a loss of 61%.Is New 90 Day High Low • Oct 22New 90-day low: ₹1.64The company is down 22% from its price of ₹2.09 on 24 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 21% over the same period.공고 • Sep 22Rubra Medicaments Limited Announces Appointment of Ms. Ritu Chhatani as Company Secretary and Compliance OfficerRubra Medicaments Limited announced that Ms. Ritu Chhatani has been appointed as the Company Secretary and Compliance Officer of the Company with effect from September 21, 2020. Ms. Ritu Chhatani is a qualified Company Secretary having an experience of over four years in the secretarial field.공고 • Sep 14Rubra Medicaments Limited Announces the Resignation of Manish Gandhi from the Post of DirectorRubra Medicaments Limited announced that the Board of Directors has accepted the Resignation of Mr. Manish Gandhi from the post of Director of the Company with effect from September 12, 2020 due to his preoccupancy in other business.주주 수익률531099IN HealthcareIN 시장7D2.3%2.1%2.0%1Y-18.4%8.0%3.6%전체 주주 수익률 보기수익률 대 산업: 531099은 지난 1년 동안 8%의 수익을 기록한 Indian Healthcare 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 531099은 지난 1년 동안 3.6%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is 531099's price volatile compared to industry and market?531099 volatility531099 Average Weekly Movement8.8%Healthcare Industry Average Movement5.6%Market Average Movement6.0%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.7%안정적인 주가: 531099의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: 531099의 주간 변동성(9%)은 지난 1년 동안 안정적이었지만 Indian 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트19914Shubham Chaudharywww.rubramed.com체크포인트 트렌드 리미티드는 인도에서 무역 사업을 하고 있습니다. 또한 컨설팅 서비스도 제공합니다. 이 회사는 이전에 Rubra Medicaments Limited로 알려졌으며 2022년 5월에 Checkpoint Trends Limited로 사명을 변경했습니다.더 보기Centuple Global Limited 기초 지표 요약Centuple Global의 순이익과 매출은 시가총액과 어떻게 비교됩니까?531099 기초 통계시가총액₹187.34m순이익 (TTM)₹15.07m매출 (TTM)₹5.74b12.4x주가수익비율(P/E)0.0x주가매출비율(P/S)531099는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표531099 손익계산서 (TTM)매출₹5.74b매출원가₹5.69b총이익₹45.79m기타 비용₹30.72m순이익₹15.07m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)2.76총이익률0.80%순이익률0.26%부채/자본 비율29.0%531099의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/03 18:35종가2026/08/03 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Centuple Global Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Jul 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹33.46, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 42x in the Healthcare industry in India. Total loss to shareholders of 5.0% over the past year.
Board Change • Jul 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. MD, CFO & Director Shubham Chaudhary is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공고 • Jun 20Centuple Global Limited Announces Board AppointmentsCentuple Global Limited at its Extra Ordinary General Meeting held on June 18, 2026, appointed Mr. Gaurav Kaushik as a Non-Executive Independent Director of the company. The company appointed Mr. Ashish Jain as a Non-Executive Independent Director of the company.
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.76 (vs ₹0.046 in FY 2025)Full year 2026 results: EPS: ₹2.76 (up from ₹0.046 in FY 2025). Revenue: ₹5.74b (up ₹5.73b from FY 2025). Net income: ₹15.1m (up ₹14.8m from FY 2025). Profit margin: 0.3% (down from 5.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 112% per year whereas the company’s share price has increased by 111% per year.
공고 • May 23Checkpoint Trends Limited to Report Q4, 2026 Results on May 30, 2026Checkpoint Trends Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹44.44, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 756% over the past three years.
Valuation Update With 7 Day Price Move • Jul 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹33.46, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 42x in the Healthcare industry in India. Total loss to shareholders of 5.0% over the past year.
Board Change • Jul 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. MD, CFO & Director Shubham Chaudhary is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공고 • Jun 20Centuple Global Limited Announces Board AppointmentsCentuple Global Limited at its Extra Ordinary General Meeting held on June 18, 2026, appointed Mr. Gaurav Kaushik as a Non-Executive Independent Director of the company. The company appointed Mr. Ashish Jain as a Non-Executive Independent Director of the company.
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.76 (vs ₹0.046 in FY 2025)Full year 2026 results: EPS: ₹2.76 (up from ₹0.046 in FY 2025). Revenue: ₹5.74b (up ₹5.73b from FY 2025). Net income: ₹15.1m (up ₹14.8m from FY 2025). Profit margin: 0.3% (down from 5.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 112% per year whereas the company’s share price has increased by 111% per year.
공고 • May 23Checkpoint Trends Limited to Report Q4, 2026 Results on May 30, 2026Checkpoint Trends Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹44.44, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 756% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹39.28, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 33x in the Healthcare industry in India. Total returns to shareholders of 130% over the past year.
Valuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹52.16, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 36x in the Healthcare industry in India. Total returns to shareholders of 1,005% over the past three years.
공고 • Mar 18Checkpoint Trends Limited Board Resignations, Effective March 18, 2026Checkpoint Trends Limited announced that based on the recommendations of Nomination and Remuneration Committee meeting held on March 18, 2026 and the Board of Directors of the Company at its meeting held on March 18, 2026 inter alia, considered and approved the following: Resignation of Ms. Bhawna Saunkhiya (DIN: 10683032) as Non- Executive and Independent Director of the Company due to pre-occupation and other personal commitments. Date of Resignation: March 18, 2026. Resignation of Mr. Saurabh (DIN: 10790325) as Non- Executive and Independent Director of the Company. due to pre-occupation and other personal commitments. Date of Resignation: March 18, 2026.
New Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹246.5m market cap, or US$2.67m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹85.00, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 38x in the Healthcare industry in India. Total returns to shareholders of 1,701% over the past three years.
Reported Earnings • Jan 29Third quarter 2026 earnings releasedThird quarter 2026 results: EPS: ₹1.05. Revenue: ₹1.74b (up ₹1.74b from 3Q 2025). Net income: ₹5.75m (up ₹5.93m from 3Q 2025). Profit margin: 0.3% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has increased by 200% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Jan 19Checkpoint Trends Limited to Report Q3, 2026 Results on Jan 28, 2026Checkpoint Trends Limited announced that they will report Q3, 2026 results on Jan 28, 2026
Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹120, the stock trades at a trailing P/E ratio of 45.1x. Average trailing P/E is 41x in the Healthcare industry in India. Total returns to shareholders of 2,566% over the past three years.
Buy Or Sell Opportunity • Dec 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 118% to ₹109. The fair value is estimated to be ₹90.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 151% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Dec 05Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 189% to ₹110. The fair value is estimated to be ₹90.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 151% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹2.42 (vs ₹0.08 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.42 (up from ₹0.08 loss in 2Q 2025). Revenue: ₹1.09b (up ₹1.09b from 2Q 2025). Net income: ₹13.2m (up ₹13.7m from 2Q 2025). Profit margin: 1.2% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has increased by 170% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Nov 04Checkpoint Trends Limited to Report First Half, 2026 Results on Nov 12, 2025Checkpoint Trends Limited announced that they will report first half, 2026 results on Nov 12, 2025
공고 • Sep 11Checkpoint Trends Limited announced that it expects to receive funding from Rajvansh Electricals Private Limited, Golden Bio Energy Limited and other investors.Checkpoint Trends Limited announced a private placement to issue 51,436,781 Convertible warrants on September 10, 2025. The transaction involves participation of Rajvansh Electricals Private Limited for 9,074,410 warrant, Golden Bio Energy Limited for 9,074,410 warrant, Recoll Projects Private Limited for 9,074,410 warrant , Pradeep Kumar for 15,124,017 warrant and other investors. Each Warrant will be convertible into, or exchangeable for 1 (one) fully paid-up equity share within 18 (eighteen) months from the date of allotment of the Warrants. The transaction is approved by board of director and still subject to shareholder approval.
공고 • Aug 29Checkpoint Trends Limited, Annual General Meeting, Sep 29, 2025Checkpoint Trends Limited, Annual General Meeting, Sep 29, 2025, at 16:00 Indian Standard Time.
Reported Earnings • Aug 07First quarter 2026 earnings released: EPS: ₹0.16 (vs ₹0.05 in 1Q 2025)First quarter 2026 results: EPS: ₹0.16 (up from ₹0.05 in 1Q 2025). Revenue: ₹117.1m (up ₹116.1m from 1Q 2025). Net income: ₹889.0k (up 259% from 1Q 2025). Profit margin: 0.8% (down from 25% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 124% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Jul 29Checkpoint Trends Limited to Report Q2, 2025 Results on Aug 06, 2025Checkpoint Trends Limited announced that they will report Q2, 2025 results on Aug 06, 2025
Reported Earnings • May 30Full year 2025 earnings released: EPS: ₹0.05 (vs ₹0.055 in FY 2024)Full year 2025 results: EPS: ₹0.05 (down from ₹0.055 in FY 2024). Revenue: ₹5.01m (down 56% from FY 2024). Net income: ₹254.0k (down 16% from FY 2024). Profit margin: 5.1% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 14Checkpoint Trends Limited to Report Q4, 2025 Results on May 28, 2025Checkpoint Trends Limited announced that they will report Q4, 2025 results on May 28, 2025
New Risk • Mar 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$91k). Market cap is less than US$10m (₹90.0m market cap, or US$1.03m).
New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$90k). Market cap is less than US$10m (₹63.3m market cap, or US$723.2k). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
공고 • Feb 03Checkpoint Trends Limited to Report Q3, 2025 Results on Feb 12, 2025Checkpoint Trends Limited announced that they will report Q3, 2025 results on Feb 12, 2025
New Risk • Nov 12New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$94k). Market cap is less than US$10m (₹73.8m market cap, or US$874.6k). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
공고 • Nov 05Checkpoint Trends Limited to Report Q2, 2025 Results on Nov 11, 2024Checkpoint Trends Limited announced that they will report Q2, 2025 results on Nov 11, 2024
Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹9.75, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 48x in the Healthcare industry in India. Total returns to shareholders of 153% over the past three years.
공고 • Sep 16Checkpoint Trends Limited Approves Appointment of Artee Sahu as Company Secretary and Compliance OfficerCheckpoint Trends Limited announced that, the board of directors of the company at its meeting held on September 16, 2024 inter alia, has considered and approved the appointment of Ms. Artee Sahu as company secretary and compliance officer of the company. Date of Appointment is September 16, 2024. Ms. Artee Sahu is a qualified company secretary. She is expert in companies Act 2013 and SEBI (LODR) 2015.
공고 • Sep 06Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time.
New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹10m revenue, or US$123k). Market cap is less than US$10m (₹43.9m market cap, or US$522.2k). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
Valuation Update With 7 Day Price Move • Sep 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹7.64, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 49x in the Healthcare industry in India. Total returns to shareholders of 40% over the past year.
Reported Earnings • Aug 15First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹0.05. Revenue: ₹1.00m (down 50% from 1Q 2024). Net income: ₹248.0k (up ₹788.0k from 1Q 2024). Profit margin: 25% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
공고 • Aug 06Checkpoint Trends Limited to Report Q1, 2025 Results on Aug 13, 2024Checkpoint Trends Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹8.03, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 107% over the past three years.
공고 • May 26Checkpoint Trends Limited Announces Cessation of Sunil Khandalwal as Managing Director, with Effect from May 27, 2024Checkpoint Trends Limited announced that at the board meeting held on May 25, 2024, the company approved the cessation of Mr. Sunil Khandalwal as Managing Director of the Company due to the expiry of tenure and not being reappointed. Date of Cessation- With effect from May 27, 2024.
공고 • May 17Checkpoint Trends Limited to Report Q4, 2024 Results on May 25, 2024Checkpoint Trends Limited announced that they will report Q4, 2024 results at 3:30 PM, Indian Standard Time on May 25, 2024
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non Executive Independent Director Harish Surve was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹9.22, the stock trades at a trailing P/E ratio of 32x. Average trailing P/E is 38x in the Healthcare industry in India. Total returns to shareholders of 281% over the past three years.
Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.004 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.10 (up from ₹0.004 in 3Q 2023). Revenue: ₹1.71m (down 19% from 3Q 2023). Net income: ₹570.0k (up ₹548.0k from 3Q 2023). Profit margin: 33% (up from 1.0% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹9.27, the stock trades at a trailing P/E ratio of 49.4x. Average trailing P/E is 47x in the Healthcare industry in India. Total returns to shareholders of 331% over the past three years.
공고 • Jan 29Checkpoint Trends Limited to Report Q3, 2024 Results on Feb 07, 2024Checkpoint Trends Limited announced that they will report Q3, 2024 results on Feb 07, 2024
공고 • Jan 25Checkpoint Trends Limited Announces Resignation of Komal Behl, Company SecretaryCheckpoint Trends Limited announced that Ms. Komal Behl, Company Secretary of the Company has tendered her resignation with effect from January 24, 2024 (at the end of working hours) due to personal reason.
Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹4.87, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 41x in the Healthcare industry in India. Total returns to shareholders of 106% over the past three years.
Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹0.47 (vs ₹0.02 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.47 (up from ₹0.02 in 2Q 2023). Revenue: ₹2.90m (down 19% from 2Q 2023). Net income: ₹2.59m (up ₹2.49m from 2Q 2023). Profit margin: 89% (up from 2.6% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Oct 28Checkpoint Trends Limited to Report First Half, 2024 Results on Nov 07, 2023Checkpoint Trends Limited announced that they will report first half, 2024 results on Nov 07, 2023
공고 • Aug 31Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time.
Reported Earnings • Aug 17First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₹2.00m (down 61% from 1Q 2023). Net loss: ₹540.0k (down 478% from profit in 1Q 2023).
공고 • Aug 03Checkpoint Trends Limited to Report Q1, 2024 Results on Aug 11, 2023Checkpoint Trends Limited announced that they will report Q1, 2024 results on Aug 11, 2023
Reported Earnings • May 28Full year 2023 earnings releasedFull year 2023 results: Revenue: ₹11.6m (down 42% from FY 2022). Net loss: ₹785.0k (loss widened 115% from FY 2022).
공고 • May 19Checkpoint Trends Limited to Report Q4, 2023 Results on May 26, 2023Checkpoint Trends Limited announced that they will report Q4, 2023 results on May 26, 2023
Reported Earnings • Feb 15Third quarter 2023 earnings releasedThird quarter 2023 results: EPS: ₹0.004. Revenue: ₹2.11m (down 51% from 3Q 2022). Net income: ₹22.0k (up ₹430.0k from 3Q 2022). Profit margin: 1.0% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.
공고 • Jan 31Checkpoint Trends Limited to Report Q3, 2023 Results on Feb 13, 2023Checkpoint Trends Limited announced that they will report Q3, 2023 results on Feb 13, 2023
공고 • Dec 08Checkpoint Trends Limited Announces Company Secretary ChangesCheckpoint Trends Limited announced that Ms. Ritu Chattani, Company Secretary of the Company has tendered her resignation with immediate effect for better prospectus. Ms. Komal Behl, has been appointed as the CompanySecretary and Compliance Officer of the Company with immediate effect. Ms. Komal Behl is a qualified Company Secretary. She is having an experience of over five years in the secretarial field. She has worked as a professional prior to joining Company. Ms. Komal Behl is not related to any of the directors of the company.
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.03 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.02 (down from ₹0.03 in 2Q 2022). Revenue: ₹3.60m (up 39% from 2Q 2022). Net income: ₹93.0k (down 34% from 2Q 2022). Profit margin: 2.6% (down from 5.4% in 2Q 2022). The decrease in margin was driven by higher expenses.
공고 • Oct 30Checkpoint Trends Limited to Report First Half, 2023 Results on Nov 10, 2022Checkpoint Trends Limited announced that they will report first half, 2023 results on Nov 10, 2022
공고 • Aug 12Rubra Medicaments Limited, Annual General Meeting, Sep 30, 2022Rubra Medicaments Limited, Annual General Meeting, Sep 30, 2022, at 11:00 Indian Standard Time.
공고 • Aug 03Rubra Medicaments Limited to Report Q1, 2023 Results on Aug 11, 2022Rubra Medicaments Limited announced that they will report Q1, 2023 results on Aug 11, 2022
공고 • May 14Rubra Medicaments Limited to Report Fiscal Year 2022 Results on May 25, 2022Rubra Medicaments Limited announced that they will report fiscal year 2022 results on May 25, 2022
공고 • Feb 02Rubra Medicaments Limited to Report Q3, 2022 Results on Feb 11, 2022Rubra Medicaments Limited announced that they will report Q3, 2022 results on Feb 11, 2022
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹3.00, the stock trades at a trailing P/E ratio of 61.4x. Average trailing P/E is 29x in the Healthcare industry in India. Total returns to shareholders of 43% over the past three years.
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹2.71, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 36x in the Healthcare industry in India. Total returns to shareholders of 27% over the past three years.
Is New 90 Day High Low • Feb 17New 90-day low: ₹1.87The company is down 12% from its price of ₹2.13 on 19 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 23% over the same period.
Reported Earnings • Feb 14Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.00m (down 20% from 3Q 2020). Net income: ₹11.0k (down 94% from 3Q 2020). Profit margin: 1.1% (down from 15% in 3Q 2020).
공고 • Feb 01Rubra Medicaments Limited to Report Q3, 2021 Results on Feb 12, 2021Rubra Medicaments Limited announced that they will report Q3, 2021 results on Feb 12, 2021
Is New 90 Day High Low • Dec 02New 90-day high: ₹2.22The company is up 14% from its price of ₹1.95 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 30% over the same period.
Valuation Update With 7 Day Price Move • Nov 04Market bids up stock over the past weekAfter last week's 20% share price gain to ₹2.16, the stock is trading at a trailing P/E ratio of 37.4x, up from the previous P/E ratio of 31.2x. This compares to an average P/E of 35x in the Healthcare industry in India. Total return to shareholders over the past three years is a loss of 61%.
Is New 90 Day High Low • Oct 22New 90-day low: ₹1.64The company is down 22% from its price of ₹2.09 on 24 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 21% over the same period.
공고 • Sep 22Rubra Medicaments Limited Announces Appointment of Ms. Ritu Chhatani as Company Secretary and Compliance OfficerRubra Medicaments Limited announced that Ms. Ritu Chhatani has been appointed as the Company Secretary and Compliance Officer of the Company with effect from September 21, 2020. Ms. Ritu Chhatani is a qualified Company Secretary having an experience of over four years in the secretarial field.
공고 • Sep 14Rubra Medicaments Limited Announces the Resignation of Manish Gandhi from the Post of DirectorRubra Medicaments Limited announced that the Board of Directors has accepted the Resignation of Mr. Manish Gandhi from the post of Director of the Company with effect from September 12, 2020 due to his preoccupancy in other business.
